Evocalcet
Chemical compound
- H05BX06 (WHO)
- 2-[4-[(3S)-3-[[(1R)-1-Naphthalen-1-ylethyl]amino]pyrrolidin-1-yl]phenyl]acetic acid
- 870964-67-3
- 71242808
- DB12388
- E58MLH082P
- D11063
- DTXSID101132784
Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism.[1] It acts as a calcium-sensing receptor agonist.[2]
In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on dialysis.[3]
References
- ^ Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, et al. (2018). "A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro". PLOS ONE. 13 (4): e0195316. Bibcode:2018PLoSO..1395316K. doi:10.1371/journal.pone.0195316. PMC 5882164. PMID 29614098.
- ^ Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, et al. (June 2018). "Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism". Bioorganic & Medicinal Chemistry Letters. 28 (11): 2055–2060. doi:10.1016/j.bmcl.2018.04.055. PMID 29724589.
- ^ "Kyowa Hakko Kirin Launches Orkedia Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan" (Press release). Kyowa Hakko Kirin. May 22, 2018.
- v
- t
- e
Calcium homeostasis (H05)
- Abaloparatide
- Palopegteriparatide
- Parathyroid gland extract
- Teriparatide
- Recombinant human parathyroid hormone
Calcitonin derivatives | |
---|---|
Calcimimetics | |
Other |
This hormonal preparation article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e